Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197763 | 0.82 | MAPT (0.54) | NOS2MRGPRX4KDM4EMAPTTDP1 | |
| SCHEMBL23677222 | 0.82 | NOS2 (0.46) | NOS2MRGPRX4MAOAMAOBVCAM1 | |
| SCHEMBL11028837 | 0.81 | MRGPRX4 (0.53) | MRGPRX4MAOAMAOBTDP1CYP2D6 | |
| Hydrochloric Acid SCHEMBL27743366 | 0.81 | MAPT (0.52) | NOS2MRGPRX4KDM4EMAPTTDP1 | |
| SCHEMBL6212985 | 0.79 | XDH (0.60) | MRGPRX4MAOAMAOBXDHSLC6A4 | |
| SCHEMBL11329798 | 0.79 | MAPT (0.53) | MRGPRX4KDM4EMAPTTDP1CYP2D6 | |
| SCHEMBL11031302 | 0.79 | MEN1 (0.48) | MRGPRX4KDM4EMAPTSLC6A2SLC6A4 | |
| SCHEMBL4918518 | 0.78 | AR (0.47) | NOS2MRGPRX4MAOAMAOBKDM4E | |
| SCHEMBL7050401 | 0.78 | MAOA (0.61) | NOS2MRGPRX4MAOAMAOBVCAM1 | |
| SCHEMBL31441456 | 0.78 | MAOA (0.61) | NOS2MRGPRX4MAOAMAOBVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1812113-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | Argenta Discovery Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1776982-A1 | Pyrimidine compounds as histamine modulators | Argenta Discovery Limited (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1776982-A1 | Pyrimidine compounds as histamine modulators | Argenta Discovery Limited (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1767537-A1 | Pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006050965-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | NOS2 3232/4885MRGPRX4 92/4885MAOA 1938/4885 |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | HRH4, HRH3, HRH2 | NOS2 4414/4885MRGPRX4 62/4885MAOA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.